Alps Advisors Inc. Sells 96,998 Shares of Danaher Corporation (DHR)
Alps Advisors Inc. reduced its position in shares of Danaher Corporation (NYSE:DHR) by 68.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,860 shares of the conglomerate’s stock after selling 96,998 shares during the period. Alps Advisors Inc.’s holdings in Danaher Corporation were worth $3,848,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GQG Partners LLC acquired a new stake in Danaher Corporation in the second quarter valued at $101,000. Proficio Capital Partners LLC raised its holdings in Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 598 shares in the last quarter. Monetary Management Group Inc. raised its holdings in Danaher Corporation by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after acquiring an additional 150 shares in the last quarter. Acrospire Investment Management LLC raised its holdings in Danaher Corporation by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Motco raised its holdings in Danaher Corporation by 8.8% in the second quarter. Motco now owns 2,011 shares of the conglomerate’s stock valued at $170,000 after acquiring an additional 163 shares in the last quarter. 75.56% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/11/23/alps-advisors-inc-sells-96998-shares-of-danaher-corporation-dhr.html.
Danaher Corporation (NYSE DHR) opened at $93.76 on Thursday. The company has a market cap of $65,512.09, a PE ratio of 24.21, a PEG ratio of 2.24 and a beta of 1.02. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Corporation has a 12-month low of $76.27 and a 12-month high of $94.24.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the consensus estimate of $0.95 by $0.05. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.87 earnings per share. research analysts expect that Danaher Corporation will post 3.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were given a dividend of $0.14 per share. The ex-dividend date was Thursday, September 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. Danaher Corporation’s dividend payout ratio is currently 16.52%.
Several analysts recently issued reports on DHR shares. Zacks Investment Research raised shares of Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Thursday, October 5th. Cowen and Company reaffirmed a “buy” rating and issued a $90.00 price target on shares of Danaher Corporation in a report on Wednesday, October 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $95.00 price target on shares of Danaher Corporation in a report on Friday, August 4th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $83.00 price target on shares of Danaher Corporation in a report on Tuesday, September 26th. Finally, Robert W. Baird upped their price target on shares of Danaher Corporation from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Danaher Corporation presently has a consensus rating of “Buy” and a consensus target price of $93.31.
In other news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William King sold 43,688 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the transaction, the insider now owns 45,748 shares of the company’s stock, valued at approximately $3,790,679.28. The disclosure for this sale can be found here. Insiders have sold 317,498 shares of company stock valued at $28,838,801 in the last 90 days. Insiders own 12.20% of the company’s stock.
Danaher Corporation Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.